TY - JOUR T1 - Estimation of the case fatality rate based on stratification for the COVID-19 outbreak JF - medRxiv DO - 10.1101/2020.05.23.20111484 SP - 2020.05.23.20111484 AU - Byungwon Kim AU - Seonghong Kim AU - Woncheol Jang AU - Sungkyu Jung AU - Johan Lim Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/26/2020.05.23.20111484.abstract N2 - This work is motivated by the recent worldwide pandemic of the novel coronavirus disease (COVID-19). When an epidemiological disease is prevalent, estimating the case fatality rate, the proportion of deaths out of the total cases, accurately and quickly is important as the case fatality rate is one of the crucial indicators of the risk of a disease. In this work, we propose an alternative estimator of the case fatality rate that provides more accurate estimate during an outbreak by reducing the downward bias (underestimation) of the naive CFR, the proportion of deaths out of confirmed cases at each time point, which is the most commonly used estimator due to the simplicity. The proposed estimator is designed to achieve the availability of real-time update by using the commonly reported quantities, the numbers of confirmed, cured, deceased cases, in the computation. To enhance the accuracy, the proposed estimator adapts a stratification, that allows the estimator to use information from heterogeneous strata separately. With the COVID-19 cases of China, South Korea and the United States, we numerically show the proposed stratification-based estimator plays a role of providing an early warning about the severity of a epidemiological disease that estimates the final case fatality rate accurately and shows faster convergence to the final case fatality rate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementW.J. and B.K. were supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2017R1A2B2012816). S.J. and B.K. were supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2019R1A2C2002256).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The article does not have any clinical data. All data used in the analysis are available online in public.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDaily updated estimates of CFRs (1. Age-group stratified CFRs in South Korea, 2. State stratified CFRs in the United States, 3. Province stratified CFRs in China, and 4. Country stratified global CFRs) are posted online. https://sungkyujung.github.io/covid19cfr/ ER -